Losartan Potassium Tablet, Film Coated
Product Images NDC 70518-2132

Losartan Potassium is a 25 mg tablet available in a quantity of 90 at RX only. The tablet was manufactured by Aurohindo Pharma, Hyderabad, India 500 072 and has the NDC #: 70518-2132-01. The medication should be kept out of the reach of children and stored at 20-25°C (88-77°F); excursions permitted at 15-30°C (59-86°F) as per USP. For usage instructions, check the package insert. The tablet was repackaged by RemedyRepack Ine., Indiana, PA 15701, 724.465.8762.*

Losartan Potassium is a medication in the form of a tablet, with a strength of 25 mg. It comes in a pack of 90 and is available by prescription only. The NDC number is 70518-2132-02 and the lot number needs to be filled in. The medication is manufactured by Aurohindo Pharma in Hyderabad, India. It is advised to keep the medication away from children and to follow the directions in the package. The medication can be stored at a temperature ranging from 15°C to 30°C (59-86°F) with excursions permitted up to 20-25°C (88-77°F), according to USP. The medication is repackaged by RemedyRepack Inc. in Indiana, PA with their phone number being 724.465.8762.*

Losartan Potassium is a medication available in tablet form with a strength of 25mg. The package contains 30 tablets and is prescribed only with a prescription. The manufacturer of this medication is Aurobindo Pharma in Hyderabad, India, and the repackager is RemedyRepack Ine in Indiana, PA, USA. The medication should be kept out of reach of children and stored at 20-25°C (88-77°F). Please refer to the package insert for further instructions. The lot number, NDC number, and expiration date are listed on the package.*

Losartan Potassium is a medication in tablet form, with each tablet containing 25 mg. The quantity provided is 6 tablets, and this medicine requires a prescription to use. The product is identified with NDC #: 70518-2132-04 and has a LOT number, but the expiration date is not available. The source NDC for the medication is 65862-0201-99 and it is manufactured by Aurobindo Pharma in Hyderabad, India. The consumer is advised to store this medication at a temperature of 20-25°C (88-77°F), with excursions permitted up to 15-30°C (59-86°F), and keep it away from children. The package insert should be consulted for directions on how to use. RemedyRepack is the entity that repackaged the medication and is located in Indiana, PA.*

Losartan Potassium is a medication with a strength of 25 mg and is available in tablet form. This medication is prescribed only and comes in a quantity of 6 tablets. The NDC number for this medication is 70518-2132-05 and its LOT number and expiration date are not available. The source NDC is 65862-0201-90 and the manufacturer of this medication is Aurobindo Pharma, located in Hyderabad, India. It is important to keep this medication out of the reach of children and to follow the directions for use found in the package insert. This medication should be stored between 20-25°C (88-77°F) with some excursions allowed at 15-30°C (59-86°F) as permitted by USP. The medication has been repackaged by RemedyRepack Inc., located in Indiana, PA 15701, and their contact number is 724-465-8762.*

Losartan Potassium is a medication in tablet form, with a strength of 25 mg. This medication is available in a package of 30 tablets, and can only be obtained with a prescription. The National Drug Code (NDC) number for this medication is 70518-2132-00. Aurohindo Pharma, based in Hyderabad, India, is the manufacturer of this medication. It is important to keep this medication, including its packaging, out of the reach of children. Users should refer to the package insert for directions and store it at a temperature of 20-25°C (88-77°F) with excursions permitted o 15-30°C (59-86°F) according to USP standards. The medication was repackaged by RemedyRepack Inc. in Indiana, PA 15701.*

This appears to be a clinical study result that compares the adjusted risk reduction of Atenolol and Losartan Potassium. The study was conducted for a period of 66 months and the risk reduction percentage was found to be 13%. However, the text does not provide any detail on the nature or purpose of the study.*

This is a table displaying the Primary Endpoint Events' within Demographic Subgroups for a study. The table includes demographic information such as age, gender, race, and medical history. However, it is unclear what the study is about or what the primary endpoint event is.*

This text appears to be a table showing the percentage of patients with an event and some information about risk reduction and statistical significance. The table compares the effects of Losttan Potassium to a placebo. The risk reduction is given as 16.1% with a p-value of 0.022. However, without context or additional information, it is impossible to determine what event or condition is being studied.*